Based on the results of these preclinical studies, a multicenter clinical study was initiated to determine the safety and efficacy of CD19-directed GC007F cells in treating patients with CD19+ relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.